How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/glucosylceramide-beta-glucosidase-deficiency.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Glucosylceramide beta-glucosidase deficiency — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Glucosylceramide beta-glucosidase deficiency (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Glucosylceramide beta-glucosidase deficiency, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cerdelga	ELIGLUSTAT	Sanofi	Glucosylceramide Synthase Inhibitor [EPC]	Ceramide glucosyltransferase	2014-01-01
Zavesca	MIGLUSTAT	AstraZeneca	Glucosylceramide Synthase Inhibitor [EPC]	Lysosomal alpha-glucosidase	2003-01-01
Cerezyme	IMIGLUCERASE	Sanofi	Hydrolytic Lysosomal Glucocerebroside-specific Enzyme [EPC]		1994-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Sanofi · 2 drugs in Glucosylceramide beta-glucosidase deficiency
· 1 drug in Glucosylceramide beta-glucosidase deficiency
AstraZeneca · 1 drug in Glucosylceramide beta-glucosidase deficiency

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Glucosylceramide beta-glucosidase deficiency:

Cite this brief

Drug Landscape (2026). Glucosylceramide beta-glucosidase deficiency — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/glucosylceramide-beta-glucosidase-deficiency. Accessed 2026-06-10.

Glucosylceramide beta-glucosidase deficiency full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing